Iván Sanz-Muñoz, Irene Arroyo-Hernantes, Alejandro Martín-Toribio, Marina Toquero-Asensio, Javier Sánchez-Martínez, Carla Rodríguez-Crespo, Silvia Rojo-Rello, Marta Domínguez-Gil, Marta Hernández-Pérez, Eduardo Tamayo, Ruth Gil-Prieto, Ángel Gil-de-Miguel, José M Eiros
{"title":"西班牙流感疾病负担:一项五季研究(2015-2020)。","authors":"Iván Sanz-Muñoz, Irene Arroyo-Hernantes, Alejandro Martín-Toribio, Marina Toquero-Asensio, Javier Sánchez-Martínez, Carla Rodríguez-Crespo, Silvia Rojo-Rello, Marta Domínguez-Gil, Marta Hernández-Pérez, Eduardo Tamayo, Ruth Gil-Prieto, Ángel Gil-de-Miguel, José M Eiros","doi":"10.1080/21645515.2024.2440206","DOIUrl":null,"url":null,"abstract":"<p><p>Influenza accounts for 30% of the total morbidity and mortality in the European Union. However, the specific burden in different European countries is largely unknown, and more research is needed to ascertain the reality of this disease. In this retrospective study, we analyzed the burdens of hospitalization, intensive care unit (ICU) admission and in-hospital mortality in Spain over five seasons (2015-2020) via publicly available Minimum Basic Datasets (MDBS). The data revealed that influenza had a major impact in Spain, with approximately 29,000 hospitalizations, 2,200 ICU admissions, and 1,600 deaths each season. In this period, approximately 7.8% of those hospitalized required ICU admission, and 5.7% died in the hospital due to influenza, with wide differences in these parameters depending on the season due to the virological characteristics of the major circulating viruses. More than 60% of those hospitalized were over 65 years of age, and approximately 82% of those who died were elderly, demonstrating that the greatest burden of hospitalization and mortality is centered on this age group. The annual direct cost of influenza was approximately €128 million per season, with more than 80% of this cost centered on people over 45 years of age.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440206"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776464/pdf/","citationCount":"0","resultStr":"{\"title\":\"Disease burden of influenza in Spain: A five-season study (2015-2020).\",\"authors\":\"Iván Sanz-Muñoz, Irene Arroyo-Hernantes, Alejandro Martín-Toribio, Marina Toquero-Asensio, Javier Sánchez-Martínez, Carla Rodríguez-Crespo, Silvia Rojo-Rello, Marta Domínguez-Gil, Marta Hernández-Pérez, Eduardo Tamayo, Ruth Gil-Prieto, Ángel Gil-de-Miguel, José M Eiros\",\"doi\":\"10.1080/21645515.2024.2440206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Influenza accounts for 30% of the total morbidity and mortality in the European Union. However, the specific burden in different European countries is largely unknown, and more research is needed to ascertain the reality of this disease. In this retrospective study, we analyzed the burdens of hospitalization, intensive care unit (ICU) admission and in-hospital mortality in Spain over five seasons (2015-2020) via publicly available Minimum Basic Datasets (MDBS). The data revealed that influenza had a major impact in Spain, with approximately 29,000 hospitalizations, 2,200 ICU admissions, and 1,600 deaths each season. In this period, approximately 7.8% of those hospitalized required ICU admission, and 5.7% died in the hospital due to influenza, with wide differences in these parameters depending on the season due to the virological characteristics of the major circulating viruses. More than 60% of those hospitalized were over 65 years of age, and approximately 82% of those who died were elderly, demonstrating that the greatest burden of hospitalization and mortality is centered on this age group. The annual direct cost of influenza was approximately €128 million per season, with more than 80% of this cost centered on people over 45 years of age.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"21 1\",\"pages\":\"2440206\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776464/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2440206\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2440206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Disease burden of influenza in Spain: A five-season study (2015-2020).
Influenza accounts for 30% of the total morbidity and mortality in the European Union. However, the specific burden in different European countries is largely unknown, and more research is needed to ascertain the reality of this disease. In this retrospective study, we analyzed the burdens of hospitalization, intensive care unit (ICU) admission and in-hospital mortality in Spain over five seasons (2015-2020) via publicly available Minimum Basic Datasets (MDBS). The data revealed that influenza had a major impact in Spain, with approximately 29,000 hospitalizations, 2,200 ICU admissions, and 1,600 deaths each season. In this period, approximately 7.8% of those hospitalized required ICU admission, and 5.7% died in the hospital due to influenza, with wide differences in these parameters depending on the season due to the virological characteristics of the major circulating viruses. More than 60% of those hospitalized were over 65 years of age, and approximately 82% of those who died were elderly, demonstrating that the greatest burden of hospitalization and mortality is centered on this age group. The annual direct cost of influenza was approximately €128 million per season, with more than 80% of this cost centered on people over 45 years of age.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.